The resource provides a look at protein localization patterns across the proteome as well as responses to events like alternative splicing and drug perturbation.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
The team compiled these proteins in three panels that could help researchers better assess plasma sample quality in protein biomarker work.
The company is currently using the model, named EDGE, in its own personalized cancer vaccine work and in collaboration with outside immunotherapy developers.
Researchers at the University of Copenhagen used mass spectrometry to analyze dental plaque from 21 individuals recovered from a medieval Danish gravesite.
Revenues in the third quarter grew to $466.6 million from $335.6 million in Q3 2017, beating the consensus Wall Street estimate of $451.7 million.
New work has looked at how common HLA peptide splicing is, which has significance for immunotherapy and infectious disease research.
The company reported $5.92 billion in revenues for the quarter, driven by growth across its four business segments.
Agena has an ongoing partnership with Guangzhou-based DaRui to develop MassArray-based diagnostics for cancer and inherited diseases for the Chinese market.
The company's revenues were up, but fell short of Wall Street estimates as growth in the European market was hampered by lower sales to pharma customers there.
The approach could be particularly useful for harmonizing data from large multi-site efforts as proteomics experiments continue to grow in size and complexity.
A preliminary analysis based on high-resolution metabolomics pointed to three blood plasma metabolites with apparent ties to active, pulmonary tuberculosis.
The tool allows users to search for unexpected modifications and other phenomena that are difficult to identify using conventional mass spec search software.
The scientists developed a metabolomic panel capable of predicting BMI and identifying subsets of at-risk patients with apparently healthy BMIs.
A team from the EPFL has identified the chemical NTCB as a potential digestion reagent for middle-down work, though bioinformatic hurdles still remain.
The group's meeting this week evidenced the ongoing shift towards analyzing proteins in the context of specific isoforms, complexes, and cells.
The agreement is part of a larger effort by the company to apply its Signabody affinity reagents to toxicity biomarker work and other areas of drug development.
Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
The companies will jointly promote Visiopharm's Phenomap image-analysis software alongside Fluidigm's Hyperion imaging system and related products.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.